HerediGENE® is a diagnostic multi-gene test for hereditary cancer, which analyses 52 genes, including BRCA1 and BRCA2, which are involved in the increased risk of breast, ovarian, prostate, colorectal and other hereditary cancers.

  • It can be used as a tool for prevention. People who will be diagnosed with a pathogenic mutation can perform prophylactic surgery and pharmacotherapy, dramatically reducing the likelihood of developing this cancer.
  • It offers information to the doctor about personalized surgical and pharmaceutical treatment for their patients.
  • It can be used to identify family members at risk of cancer.
Who should have the gene test for hereditary cancer
  • All individuals with breast cancer according to global guidelines (American Society of Breast Surgeons)
  • Individuals with any type of cancer at an early age
  • Individuals with bilateral breast and/or ovarian cancer
  • Individuals with the same type of cancer occurring in close relatives and cancer incidence in multiple generations of a family
  • Individuals with rare tumors at any age
  • Individuals with first-degree relatives who have had cancer at an early age or have a known gene mutation.
  • Individuals who develop hundreds or thousands of polyps
  • Men with breast cancer

Cancer Types
Breast, Colorectal, Prostate, Pancreatic, Ovarian, Gastric, Melanoma, Thyroid, Kidney, Endometrial

Cancer Syndromes
Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Cowden Syndrome, Li-Fraumeni Syndrome, Peutz-Jeghers Syndrome, Familial Adenomatous Polyposis, Von-Hippel Lindau Syndrome, Multiple Endocrine Neoplasia, Other.

Test Specifications

A person with an inherited pathogenic mutation is at increased risk for developing certain type of cancer. The gene profile therefore offers important information for the treatment of patients and the management of themselves and their families.

The HerediGENE® analyzes 52 genes, which are involved in the cancer susceptibility, 21 of which are related to Homologous Recombination (HR).

  • It helps doctors choose the best surgical and pharmaceutical plan for their patients.
  • It identifies which family members are at increased risk of developing cancer.
  • t determines the individuals who do not carry a pathogenic mutation and relieves them of the stress of the occurrence of hereditary cancer.

Why HerediGENE

  • The HerediGENE® test is designed to ensure maximum sensitivity and accuracy. Advanced Next Generation Sequencing Technology (NGS) is used and all findings are classified using the most reliable, updated databases from our Bioinformatics department.
  • Many genes are analyzed simultaneously using just a small amount of blood or saliva in a very short time and at a low cost.
  • Continuous support is provided to the doctor and the patient by our experienced scientific team
  • Free Genetic Counselling is provided. Detailed family medical history and genetic counselling before, during and after the examination.

The HerediGENE® test analyses the following genes:

ColonBreastPancreasOvarianGastricMelanomaEndometrialEndocrineProstateHRDAssociated Syndrome
APCAPCAPC APCFamilial Adenomatous Polyposis
ATMATMATMATMATMAtaxia Telangilectasia (recessive)
BMPR1ABMPR1AJuvenile Polyposis Sydrome
BRCA1BRCA1BRCA1BRCA1BRCA1BRCA1Hereditary Breast and Ovarian Cancer
BRCA2BRCA2BRCA2BRCA2BRCA2BRCA2Hereditary Breast and Ovarian Cancer, Fanconi anaemia FA-D1 (recessive)
BRIP1BRIP1BRIP1Fanconi anaemia FA-J (recessive)
CDH1CDH1Hereditary diffuse gastric cancer
CDKN2ACDKN2AFamilial Atypical Mole-Malignant Melanoma Syndrome (FAMMM)
FANCAFanconi anaemia FA-A (recessive)
FANCLFanconi anaemia FA-L (recessive)
FANCMFanconi anaemia FA-M (recessive)
MEN1Multiple endocrine neoplasia Type1
MLH1MLH1MLH1MLH1MLH1Lynch Syndrome / Constitutional mismatch repair deficiency (CMMRD) syndrome (recessive)
MRE11Ataxia-telanglectasia-like disorder (recessive)
MSH2MSH2MSH2MSH2MSH2Lynch Syndrome
MSH3Adenomatous Polyposis (recessive)
MSH6MSH6MSH6MSH6Lynch Syndrome
MUTYHMUTYH-associated polyposis
NBNNBNNijmegen breakage syndrome (recessive)
NF1NF1NF1NF1Neurofibromatosis Type1
NTHL1Adenomatous Polyposis (recessive
PALB2PALB2PALB2PALB2PALB2Fanconi anaemia FA-N (recessive)
PMS2PMS2PMS2Lynch Syndrome
POLEAdenomatous Polyposis
POLD1Adenomatous Polyposis
RAD50RAD50Nijmegen breakage syndrome like disorder (recessive)
RAD51CRAD51CRAD51CFanconi anaemia FA-O (recessive)
RAD51DRAD51DRAD51DFanconi anaemia (recessive)
RETMultiple endocrine neoplasia Type2
SMAD4SMAD4Juvenile Polyposis / Hereditary hemorhagic telanglectasia (HHT)
SMARCA4AD small cell carcinoma of the ovary hypercalcemic type (SCCOTH), AD rhabdoid tumor predisposed lion syndrome type 2 (RTPS2)
STK11STK11STK11STK11STK11STK11Peutz-Jeghers Sydrome
TP53TP53TP53TP53TP53Li-Fraumeni Sydrome
VHLvon Hippel-Lindau Sydrome


Frequently Asked Questions

What types of cancer does it cover?

The examination mainly covers the occurrence of breast and ovarian, prostate, colorectal, pancreatic, kidney, gastric, thyroid and melanoma cancers.

Are BRCA1/2 genes included?

Yes, the BRCA1/2 genes are included in addition to 41 more genes shown in the panel.

If a pathogenic mutation is found, should all family members be tested?

The results obtained by the test are useful for the entire family, as it is enough for a person to inherit a mutation from one parent, to be at increased risk of developing cancer. A child whose parent is a mutant carrier has a 50% chance of inheriting the mutation. More distant relatives are also at risk of carrying the mutation. Individuals who may be carriers of inherited gene mutation can be identified by referral for genetic testing. Note that hereditary cancer susceptibility syndromes can be associated with many different types of cancer. Therefore, a mutation detected in the sample for breast or ovarian cancer may be associated with an increased risk of pancreatic or prostate cancer.

In how many days will the results be available?

Results will be available in 20 business days.

What type of sample is required for the test?

Whole peripheral blood in EDTA vials (2 vials) or saliva in a special kit supplied by our company.

Is blood sampling performed at the Genekor facility?

No, the company does not perform blood samplings, so you should contact us at 210-6032138 and we will guide you.

Is the test covered by any public/private insurance?

For cost coverage, please contact the secretariat here.

Following the launch of e-prescribing for BRCA 1,2 gene mutation testing for hereditary breast and ovarian cancer, please find below the Electronic Prescription Template with the relevant detailed e-prescribing instructions for BRCA 1,2 genes for the 4 different cases.

Case 1: Women diagnosed with Ca breast before the age of 45
Case 2: Women diagnosed with Breast Ca at age greater than or equal to 45 years with Family History
Case 3: Women diagnosed with malignant epithelial neoplasm of the ovary
Case 4: Women with a known BRCA1/2 mutation in the family


How do I make the payment for the test?

Payment can be made by bank transfer or debit/credit card

How I send the sample and receive the results?

Regarding the receipt of the sample, please contact the secretariat. The results are shared with your doctor and with you via email.

How to order the test?

Our Customer Service Team is committed to answer your questions with regards to the services offered by Genekor. If you would like to order any of the tests that Genekor performs please contact us directly.


*To complete the test, you are required to complete and send the Consent form that you will find on the link below.

If you want to send us your sample, please contact us in order to arrange all procedures.

*For more information on scientific content please contact:

*Download the promotional brochure here.

*Order in the United Arab Emirates here.